The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation (SUSTAIN)
Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo Controlled Clinical Trial for the Assessment of Lipid Trends and Safety of RVX000222 in Statin Treated Subjects With Low Baseline HDL-C Concentrations
Sponsor: Resverlogix Corp
This PHASE2 trial investigates Coronary Artery Disease and Dyslipidemia and is currently completed. Resverlogix Corp leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Aug 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Resverlogix Corp
- The Cleveland Clinic
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bloemfontein, South Africa , Cape Town, South Africa , Chatsworth, South Africa , Die Wilgers, South Africa , East Burger Street, South Africa , Eloffsdal, South Africa , Goodwood, South Africa , Halfway House, South Africa , Johannesburg, South Africa , Kraaifontein, South Africa and 14 more locations